Regulatory Authorities Worldwide are Scrutinizing GDPs During Inspections

Regulators worldwide are increasingly scrutinizing pharmaceutical manufacturers’ good distribution practices (GDPs) during GMP inspections as GDP regulations continue to proliferate, says an industry representative who discusses how to comply with different regulations and notes some of the challenges in instituting robust GDPs. USP is the latest player in the increasingly crowded GDP arena.